



E1761
JACC April 5, 2011
Volume 57, Issue 14



IMPROVED OUTCOMES WITH DRUG ELUTING VERSUS BARE METAL STENTS IN SAPHENOUS VEIN GRAFT INTERVENTION: A REPORT FROM THE EVALUATION OF DRUG-ELUTING STENTS AND ISCHEMIC EVENTS (EVENT) REGISTRY

i2 Poster Contributions

Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 3:30 p.m.-4:45 p.m.

Session Title: PCI - DES II

Abstract Category: 16. PCI - DES (clinical/outcomes)

Session-Poster Board Number: 2504-594

Authors: *Paul H. Tolerico, David J. Cohen, Neal S. Kleiman, Peter B. Berger, Emmanouil S. Brilakis, Robert N. Piana, Salim Shammo, Michelle J. Keyes, Kevin F. Kennedy, Joseph M. Massaro, Jorge F. Saucedo, York Hospital, York, PA, The University of Oklahoma Health Sciences Center, Oklahoma City, OK*

Background: The benefit of drug-eluting stents (DES) compared with bare metal stents (BMS) in saphenous vein graft (SVG) intervention remains controversial.

Methods: We analyzed data from the multicenter EVENT registry to compare 1-year clinical outcomes among 684 patients who underwent SVG intervention using either DES (n=515) or BMS (n=169). The primary endpoint was major adverse cardiovascular events (MACE), a composite of death, MI, and target lesion revascularization (TLR), between discharge and 1-year follow-up.

Results: Baseline characteristics were similar except DES patients were less likely to be male, had a lower incidence of angiographic thrombus, and were less likely to be treated with an embolic protection device. Total stent length was longer and maximum balloon diameter was smaller among DES patients as well. In-hospital outcomes were similar. After propensity score stratification to adjust for differences between groups, the adjusted risk of 1-year MACE was lower with DES than with BMS (adjusted HR 0.56, p=0.003) with similar adjusted hazard ratios for each endpoint component, including TLR. This reduction in MACE for DES patients persisted after excluding in-hospital events and analyzing only outcomes from hospital discharge to one year (adjusted HR 0.48, p<0.01).

Conclusions: SVG intervention with DES compared to BMS resulted in less MACE at one year with no evidence of increased complications or mortality.

	Unadjusted Event Rate, DES	Unadjusted Event Rate, BMS	Adjusted Hazard Ratio (HR) (95% CI)	Multivariate P- value
Out-of-Hospital:				
MACE (Death/MI/TLR)	10.3%	13.8%	0.48 (0.27-0.84)	<0.01
Death	1.0%	2.5%	0.49 (0.14-1.74)	0.34
MI	3.5%	5.7%	0.50 (0.20-1.26)	0.14
TLR	8.0%	7.5%	0.68 (0.34-1.37)	0.28
One Year:				
MACE (Death/MI/TLR)	17.4%	24.2%	0.56 (0.33-0.79)	0.003
Death/MI	11.7%	19.3%	0.49 (0.29-0.83)	0.008
Death	2.0%	3.7%	0.43 (0.13-1.46)	0.18
TLR	8.4%	7.5%	0.69 (0.33-1.41)	0.30